Status:

COMPLETED

Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever

Lead Sponsor:

Medical Corps, Israel Defense Force

Conditions:

Relapsing Fever, Tick-borne

Jarisch Herxheimer Reaction

Eligibility:

All Genders

Phase:

PHASE2

PHASE3

Brief Summary

Abstract Background Tick-Borne Relapsing Fever (TBRF) is an acute febrile illness. In Israel, TBRF is caused by Borrelia persica and is transmitted by Ornithodoros tholozani ticks. We examined the saf...

Eligibility Criteria

Inclusion

  • suspected exposure to tick-borne relapsing fever
  • after returning from field exercise in a tick-borne relapsing fever infected area
  • having a tick bite or staying in field in close proximity to a subject with tick bite sign

Exclusion

  • known sensitivity to tetracycline or doxycycline
  • febrile illness on recruitment

Key Trial Info

Start Date :

April 1 2002

Trial Type :

INTERVENTIONAL

End Date :

April 1 2003

Estimated Enrollment :

140 Patients enrolled

Trial Details

Trial ID

NCT00237016

Start Date

April 1 2002

End Date

April 1 2003

Last Update

December 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Israel Defence Forces

Tel Litwinsky, Israel